Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM4 Study as 1L Treatment for Multiple Myeloma Patients Not Treated with Stem Cell Transplantation

 Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM4 Study as 1L Treatment for Multiple Myeloma Patients Not Treated with Stem Cell Transplantation

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM4 Study as 1L Treatment for Multiple Myeloma Patients Not Treated with Stem Cell Transplantation

Shots:

  • The P-III TOURMALINE-MM4 study involves assessing Ninlaro (ixazomib) as 1L maintenance therapy vs PBO in 706 newly diagnosed patients with multiple myeloma not treated with stem cell transplantation with completed 6-12mos. of initial therapy and achieved a partial response or better
  • The P-III TOURMALINE-MM4 study results demonstrated significant improvement in PFS with consistent safety profile with previous results of Ninlaro used as a single agent and no new safety signals were identified
  • Ninlaro is an oral proteasome inhibitor being evaluated in multiple therapeutic combinations globally and has received FDA’s approval in combination with lenalidomide and dexamethasone for patients with MM who have received at least one prior therapy in Nov’2015

Click here to­ read full press release/ article | Ref: Takeda  | Image: The Boston Globe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post